semaglutide insomnia GLP-1 Sleep Changes: What Real Patients Experience Do Weight Loss Injections Affect

[DOI] [PubMed] [Google Scholar] 167.Furukawa S, Yang L, Sameshima H, Ikenoue T

found that treating patients with MASLD and type 2 diabetes with liraglutide 1.2 mg/day for 6 months led to reductions in body weight, visceral fat, transaminase levels, and liver fat content

Currently, there is limited interest in the non-GLP-1R obesity field, as sales for obesity drugs targeting alternative mechanisms are only forecast to generate a mere $310m in 2026

Eli Lilly's Zepbound and Mounjaro continue to gain market share, eroding Novo Nordisk's early first-mover advantage [Source: reuters.com/legal/litigation/health-canada-approves-first-generic-version-novo-nordisks-ozempic-2026-04-28/]